TGF-beta1 mRNA upregulation influences chronic renal allograft dysfunction
Language English Country United States Media print
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
16612332
DOI
10.1038/sj.ki.5000328
PII: S0085-2538(15)51352-5
Knihovny.cz E-resources
- MeSH
- Time Factors MeSH
- Adult MeSH
- Transplantation, Homologous * MeSH
- Immunohistochemistry MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger analysis metabolism MeSH
- Follow-Up Studies MeSH
- Graft Rejection pathology MeSH
- Retrospective Studies MeSH
- ROC Curve MeSH
- Transforming Growth Factor beta genetics metabolism MeSH
- Transforming Growth Factor beta1 MeSH
- Kidney Transplantation adverse effects MeSH
- Up-Regulation * MeSH
- Treatment Outcome MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- RNA, Messenger MeSH
- TGFB1 protein, human MeSH Browser
- Transforming Growth Factor beta MeSH
- Transforming Growth Factor beta1 MeSH
Acute rejection (AR) is a dominant risk factor for developing chronic allograft nephropathy (CAN) after kidney transplantation. CAN is characterized by progressive interstitial fibrosis. It has been associated with increased transforming growth factor (TGF)-beta1 expression, however, kinetic studies are absent. We investigated whether intragraft TGF-beta1 expression in various causes of early graft dysfunction may influence late renal allograft dysfunction. A total of 174 human renal biopsies were quantified for TGF-beta1 mRNA expression using real-time reverse transcriptase-polymerase chain reaction. Expression levels were correlated with the Banff histopathological grades, TGF-beta1 immunohistology, and clinical follow-up. TGF-beta1 was most markedly upregulated in AR, CAN, and acute tubular necrosis - delayed graft function compared to non-rejecting controls (P < 0.001). TGF-beta1 expression was heightened in borderline changes (P < 0.01), recurrence of glomerulonephritis, and cyclosporine toxicity (P < 0.05). There was no correlation between intragraft TGF-beta1 expression during AR and short-term outcome of a rejection episode. TGF-beta1 gene overexpression during CAN has been shown to be associated with the increased risk for renal allograft dysfunction 18 months after biopsy (odds ratios 9.9 vs 3.2, respectively). Intragraft TGF-beta1 mRNA expression is significantly upregulated in both AR and CAN. Thus, our results support the hypothesis that TGF-beta1 might play a key role in chronic allograft dysfunction.
References provided by Crossref.org
Molecular phenotypes of acute rejection predict kidney graft prognosis